https://www.pentara.com/publications/2026/evaluating-digital-cognitive-tests-for-clinical-use-in-alzheimers-327 https://www.pentara.com/publications/2026/efficacy-assessment-in-trials-of-complex-and-rare-diseases-a-328 https://www.pentara.com/publications/2026/time-scale-target-parameters-and-two-step-estimation-in-longitudinal-329 https://www.pentara.com/publications/2026/rns60-rescue-trial-in-acute-ischemic-stroke-post-hoc-analysis-in-330 https://www.pentara.com/publications/2026/target-product-profiles-for-treatments-to-delay-or-prevent-symptomatic-331 https://www.pentara.com/publications/2026/incorporating-patient-perspectives-into-a-composite-score-for-332 https://www.pentara.com/publications/2026/handling-missing-data-in-participants-with-baseline-but-no-post-333 https://www.pentara.com/publications/2026/biomarkers-in-patients-with-clinical-signs-of-mild-cognitive-334 https://www.pentara.com/publications/2026/phase-3-randomized-clinical-trials-of-simufilam-in-mild-to-moderate-326 https://www.pentara.com/publications/2026/a-review-of-evidence-supporting-amyloid-beta-reduction-as-a-surrogate-336 https://www.pentara.com/publications/2025/hippocampal-atrophy-on-magnetic-resonance-imaging-as-a-surrogate-317 https://www.pentara.com/publications/2025/leveraging-recent-advances-in-plasma-biomarkers-to-optimize-early-316 https://www.pentara.com/publications/2025/development-of-composite-scales-for-assessing-disease-progression-and-315 https://www.pentara.com/publications/2025/efficacy-of-ad04-an-aluminum-based-vaccine-adjuvant-in-patients-with-314 https://www.pentara.com/publications/2025/a-double-blind-controlled-trial-of-circadian-effective-light-therapy-313 https://www.pentara.com/publications/2025/development-and-validation-of-parcoms-composite-scales-for-assessing-305 https://www.pentara.com/publications/2025/time-saved-in-activities-of-daily-living-and-whole-brain-volume-post-307 https://www.pentara.com/publications/2025/evaluation-of-exploratory-fluid-biomarkers-from-a-phase-1-senolytic-306 https://www.pentara.com/publications/2025/safety-and-efficacy-of-senolytic-ubx1325-in-diabetic-macular-edema-309 https://www.pentara.com/publications/2025/donanemab-appropriate-use-recommendations-310 https://www.pentara.com/publications/2025/cohen-mansfield-agitation-inventory-total-score-as-a-measure-of-308 https://www.pentara.com/publications/2025/key-considerations-for-combination-therapy-in-alzheimers-clinical-311 https://www.pentara.com/publications/2024/results-of-the-action-galactosemia-kids-study-to-evaluate-the-effects-297 https://www.pentara.com/publications/2024/analytic-challenges-in-clinical-trials-of-early-alzheimers-disease-312 https://www.pentara.com/publications/2024/augmenting-prognostication-utilizing-activity-trackers-to-enhance-298 https://www.pentara.com/publications/2024/development-of-a-general-composite-scale-gencoms-for-progressive-299 https://www.pentara.com/publications/2024/fluid-biomarkers-in-the-context-of-amyloid-targeting-disease-modifying-300 https://www.pentara.com/publications/2024/biological-effects-of-sodium-phenylbutyrate-and-taurursodiol-in-302 https://www.pentara.com/publications/2024/evaluation-of-clinical-meaningfulness-of-fortasyn-connect-in-terms-of-304 https://www.pentara.com/publications/2024/navigating-the-complexities-of-alzheimers-clinical-trials-the-perils-338 https://www.pentara.com/publications/2024/development-and-validation-of-scacoms-a-composite-scale-for-assessing-301 https://www.pentara.com/publications/2024/safety-tolerability-and-efficacy-estimate-of-evoked-gamma-oscillation-303 https://www.pentara.com/publications/2023/assessment-of-longitudinal-advanced-pharmacy-practice-experience-295 https://www.pentara.com/publications/2023/safety-tolerability-immunogenicity-and-efficacy-of-ub-311-in-294 https://www.pentara.com/publications/2023/avoiding-future-controversies-in-the-alzheimers-disease-space-through-296 https://www.pentara.com/publications/2023/safety-tolerability-and-efficacy-of-40-hz-sensory-stimulation-for-248 https://www.pentara.com/publications/2022/using-principal-stratification-in-analysis-of-clinical-trials-293 https://www.pentara.com/publications/2022/safety-of-a-fixed-dose-coformulation-of-sodium-phenylbutyrate-and-230 https://www.pentara.com/publications/2022/feasibility-safety-and-efficacy-of-gamma-sensory-stimulation-as-a-229 https://www.pentara.com/publications/2021/impact-of-specialized-light-therapy-in-parkinsons-disease-on-mdsupdrs-219 https://www.pentara.com/publications/2020/combining-evidence-across-multiple-endpoints-with-a-global-statistical-255 https://www.pentara.com/publications/2020/in-a-pre-pivotal-diagnostic-study-amyloid-plaque-detection-in-the-lens-195 https://www.pentara.com/publications/2020/complementary-analyses-of-the-ambar-trial-impact-of-discontinuations-193 https://www.pentara.com/publications/2020/the-impact-of-a-nutritional-intervention-in-prodromal-alzheimers-196 https://www.pentara.com/publications/2019/cognitive-outcomes-of-long-term-benzodiazepine-and-related-drug-bdzr-176 https://www.pentara.com/publications/2019/alzheimers-disease-composite-score-a-post-hoc-analysis-using-data-from-175 https://www.pentara.com/publications/2019/p4-023-clinical-trial-design-for-a-phase-ii-randomized-placebo-198 https://www.pentara.com/publications/2019/the-effects-of-memantine-added-to-cholinesterase-inhibitors-on-npi-87 https://www.pentara.com/publications/2019/sib-maintenance-of-response-with-memantine-added-to-cholinesterase-33 https://www.pentara.com/publications/2019/the-assessment-of-cognition-in-translational-medicine-a-contrast-173 https://www.pentara.com/publications/2019/plasma-biomarkers-of-ad-emerging-as-essential-tools-for-drug-170 https://www.pentara.com/publications/2019/efficacy-of-memantine-added-to-cholinesterase-inhibitors-on-sib-higher-169 https://www.pentara.com/publications/2019/a-multidomain-precision-medicine-intervention-in-patients-at-risk-for-168 https://www.pentara.com/publications/2019/fda-position-statement-early-alzheimers-disease-developing-drugs-for-161 https://www.pentara.com/publications/2018/the-clinical-practice-of-risk-reduction-for-alzheimers-disease-a-36 https://www.pentara.com/publications/2018/memantine-er-maintains-patient-response-in-moderate-to-severe-6 https://www.pentara.com/publications/2018/memantine-with-cholinesterase-inhibitors-maintains-improvements-of-86 https://www.pentara.com/publications/2018/memantine-er-and-donepezil-treatment-maintains-cognitive-improvements-75 https://www.pentara.com/publications/2018/memantine-er-with-an-achei-improves-individual-sib-scores-compared-56 https://www.pentara.com/publications/2018/the-alzheimers-prevention-initiative-autosomal-dominant-alzheimers-32 https://www.pentara.com/publications/2018/extraction-of-aperiodic-components-from-a-chronological-series-wave-249 https://www.pentara.com/publications/2018/identifying-better-outcome-measures-to-improve-treatment-of-agitation-77 https://www.pentara.com/publications/2018/double-blind-controlled-trial-of-spectramax-tm-light-therapy-for-the-40 https://www.pentara.com/publications/2017/clinically-meaningful-outcomes-in-early-alzheimer-disease-a-consortia-13 https://www.pentara.com/publications/2017/p4-573-a-phase-2-multicenter-randomized-placebo-controlled-trial-to-19 https://www.pentara.com/publications/2017/p2-034-are-alzheimers-drug-failures-due-to-inactive-compounds-or-are-54 https://www.pentara.com/publications/2017/improved-detection-of-treatment-effects-in-severe-alzheimers-disease-a-142 https://www.pentara.com/publications/2017/response-across-multiple-outcome-measures-in-a-randomized-trial-of-119 https://www.pentara.com/publications/2017/cognitive-composites-domain-scores-related-to-neuroimaging-biomarkers-150 https://www.pentara.com/publications/2017/eu-us-ctad-task-force-lessons-learned-from-recent-and-current-146 https://www.pentara.com/publications/2017/24-month-intervention-with-a-specific-multinutrient-in-people-with-123 https://www.pentara.com/publications/2017/memantine-added-to-background-cholinesterase-inhibitors-reduces-115 https://www.pentara.com/publications/2017/outcomes-assessment-in-clinical-trials-of-alzheimers-disease-and-its-100 https://www.pentara.com/publications/2017/statistical-properties-of-continuous-composite-scales-and-implications-88 https://www.pentara.com/publications/2017/efficacy-of-memantine-er-on-activities-of-daily-living-a-post-hoc-81 https://www.pentara.com/publications/2016/p3-021-treatment-with-memantine-and-a-cholinesterase-inhibitor-reduces-24 https://www.pentara.com/publications/2016/immunotherapy-of-parkinsons-disease-41 https://www.pentara.com/publications/2016/cytochrome-p450-2d-mediated-metabolism-is-not-necessary-for-274 https://www.pentara.com/publications/2016/a-novel-eigenvector-based-method-to-detect-mild-alzheimers-disease-129 https://www.pentara.com/publications/2016/daily-functioning-benefits-of-adding-memantine-to-stable-104 https://www.pentara.com/publications/2016/registries-and-cohorts-to-accelerate-early-phase-alzheimers-trials-a-9 https://www.pentara.com/publications/2015/p4-304-a-time-to-event-analysis-of-the-efficacy-of-memantine-in-a-47 https://www.pentara.com/publications/2015/the-path-to-regulatory-qualification-of-low-baseline-hippocampal-29 https://www.pentara.com/publications/2015/methodological-aspects-of-the-phase-ii-study-aff006-evaluating-amyloid-3 https://www.pentara.com/publications/2015/characterization-of-the-murine-macrophage-response-to-infection-with-254 https://www.pentara.com/publications/2015/efficacy-and-tolerability-of-memantine-extended-release-added-to-52 https://www.pentara.com/publications/2015/adding-memantine-to-stable-cholinesterase-inhibitor-therapy-in-45 https://www.pentara.com/publications/2014/an-empirically-derived-composite-cognitive-test-score-with-improved-43 https://www.pentara.com/publications/2014/toll-like-receptor-agonist-augments-virus-like-particle-mediated-272 https://www.pentara.com/publications/2014/extended-release-daily-memantine-provides-increasing-cumulative-67 https://www.pentara.com/publications/2013/extended-release-memantine-28-mg-once-daily-provides-behavioral-34 https://www.pentara.com/publications/2013/disease-modifying-effect-of-etanercept-versus-sulphasalazine-on-spinal-11 https://www.pentara.com/publications/2013/designing-drug-trials-for-alzheimers-disease-what-we-have-learned-from-155 https://www.pentara.com/publications/2013/p3-274-efficacy-of-memantine-in-people-with-moderate-to-severe-48 https://www.pentara.com/publications/2013/leveraging-prior-information-to-detect-causal-variants-via-multi-287 https://www.pentara.com/publications/2013/behavioral-effects-of-extended-release-memantine-28-mg-once-daily-97 https://www.pentara.com/publications/2012/prioritizing-genetic-variants-for-causality-on-the-basis-of-278 https://www.pentara.com/publications/2012/p3-386-response-across-multiple-outcome-measures-in-a-randomized-trial-37 https://www.pentara.com/publications/2012/p4-305-introducing-a-new-tool-for-optimizing-responsiveness-to-decline-35 https://www.pentara.com/publications/2012/extended-release-memantine-28-mg-once-daily-and-sustained-behavioral-164 https://www.pentara.com/publications/2012/sustained-cognitive-improvement-with-extended-release-memantine-28-mg-55 https://www.pentara.com/publications/2012/extended-release-memantine-28-mg-once-daily-and-sustained-behavioral-16 https://www.pentara.com/publications/2011/multivariate-analysis-for-the-biobehavioral-and-social-sciences-a-93 https://www.pentara.com/publications/2011/prevention-trials-in-alzheimers-disease-an-eu-us-task-force-report-1 https://www.pentara.com/publications/2011/canonical-correlation-the-underused-method-2 https://www.pentara.com/publications/2011/p4-229-effects-of-extended-release-memantine-28-mg-day-on-cognitive-30 https://www.pentara.com/publications/2011/p3-287-composite-cognitive-endpoints-with-improved-power-to-detect-17 https://www.pentara.com/publications/2011/03-03-02-composite-cognitive-endpoints-with-improved-power-to-detect-27 https://www.pentara.com/publications/2010/p1-446-memantine-and-prevention-of-worsening-across-multiple-domains-186 https://www.pentara.com/publications/2010/p1-462-memantine-and-prevention-of-worsening-in-functional-133 https://www.pentara.com/publications/2010/p1-455-effects-of-memantine-on-global-clinical-status-in-patients-with-53 https://www.pentara.com/publications/2009/improving-discovery-of-causal-variants-in-genetic-association-studies-267 https://www.pentara.com/publications/2009/impact-of-sample-diversity-on-type-i-and-type-ii-error-in-genetic-273 https://www.pentara.com/publications/2009/comparison-of-tagging-and-imputation-to-infer-genotypes-258 https://www.pentara.com/publications/2009/s4-01-02-disease-modification-relationship-with-cognitive-decline-26 https://www.pentara.com/publications/2008/p4-376-a-phase-3-multicenter-trial-of-tarenflurbil-in-subjects-with-5 https://www.pentara.com/publications/2008/treatment-of-psychiatric-disorders-144 https://www.pentara.com/publications/2007/pharmaceutical-methods-dosing-regimes-and-dosage-forms-for-the-59 https://www.pentara.com/publications/2007/safety-tolerability-pharmacokinetics-and-a-beta-levels-after-short-57 https://www.pentara.com/publications/2007/tarenflurbil-mpc-7869-flurizan-a-selective-abeta42-lowering-agent-49 https://www.pentara.com/publications/2007/witness-and-nonwitness-childrens-violent-and-peaceful-behavior-in-12 https://www.pentara.com/publications/2006/04-03-08-efficacy-and-safety-of-mpc-7869-r-flurbiprofen-a-selective-14 https://www.pentara.com/publications/2005/02-01-05-a-placebo-controlled-double-blind-trial-of-the-selective-ab-44 https://www.pentara.com/publications/2005/sensory-mechanical-and-microscopic-evaluation-of-staling-in-low-51 https://www.pentara.com/publications/2003/individual-differences-in-the-use-of-violent-and-peaceful-behavior-in-15 https://www.pentara.com/publications/2003/statistical-comparator-interface-92 https://www.pentara.com/publications/2003/deconstructing-psychologys-quantitative-heritage-the-new-look-of-46 https://www.pentara.com/publications/1996/comparing-intent-to-treat-and-protocol-compliant-analyses-to-exposure-71